Abstract
Furazano[3,4-b]quinoxaline 1-oxides indicate significant chemical reactivity and release NO fragments in their electron impact mass spectra. A series of fused furazan N-oxide derivatives were synthesized and tested in vitro as potential NO releasing agents in the presence of L- cysteine used as a thiol cofactor. The synthesized compounds were determined using cysteine as cofactor and Griess reagent. The yield in nitrite for each compound was expressed as % NO2- (mol/mol). Compound 4c showed the higher NO releasing ability among the tested furazan N-oxide derivatives. A new class of NO-donors, Furazano[3,4-b]quinoxaline 1-Oxides hybrids was developed by joining NOdonor furoxan moiety to substituted quinoxaline 1-Oxides. It seems that lipophilicity and stereochemistry of the X substitution influences the NO donating behavior.
Keywords: Nitric oxide, NO donors, furazano[3, 4-b]quinoxaline 1-Oxides, griess.
Letters in Drug Design & Discovery
Title:In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents
Volume: 13 Issue: 5
Author(s): Kosmas I. Stoitsis, Petros Gkizis, Emmanouella Basgiouraki, John K. Gallos and Dimitra Hadjipavlou-Litina
Affiliation:
Keywords: Nitric oxide, NO donors, furazano[3, 4-b]quinoxaline 1-Oxides, griess.
Abstract: Furazano[3,4-b]quinoxaline 1-oxides indicate significant chemical reactivity and release NO fragments in their electron impact mass spectra. A series of fused furazan N-oxide derivatives were synthesized and tested in vitro as potential NO releasing agents in the presence of L- cysteine used as a thiol cofactor. The synthesized compounds were determined using cysteine as cofactor and Griess reagent. The yield in nitrite for each compound was expressed as % NO2- (mol/mol). Compound 4c showed the higher NO releasing ability among the tested furazan N-oxide derivatives. A new class of NO-donors, Furazano[3,4-b]quinoxaline 1-Oxides hybrids was developed by joining NOdonor furoxan moiety to substituted quinoxaline 1-Oxides. It seems that lipophilicity and stereochemistry of the X substitution influences the NO donating behavior.
Export Options
About this article
Cite this article as:
I. Stoitsis Kosmas, Gkizis Petros, Basgiouraki Emmanouella, K. Gallos John and Hadjipavlou-Litina Dimitra, In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents, Letters in Drug Design & Discovery 2016; 13 (5) . https://dx.doi.org/10.2174/1570180812666150923235828
DOI https://dx.doi.org/10.2174/1570180812666150923235828 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Salvianolic Acid B Inhibits Atherogenesis of Vascular Cells through Induction of Nrf2-dependent Heme Oxygenase-1
Current Medicinal Chemistry The Protective Effect of Jatrorrhizine Against Oxidative Stress in Primary Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Measurement of the Endogenous Adenosine Concentration in Humans In Vivo: Methodological Considerations
Current Drug Metabolism Inhaled Nitric Oxide in Preterm Neonates with Refractory Hypoxemia Associated to Oligohydramnios
Current Drug Discovery Technologies miR-27b-3p is Highly Expressed in Serum of Patients with Preeclampsia and has Clinical Significance
Endocrine, Metabolic & Immune Disorders - Drug Targets Meet Our Editorial Board Member:
Recent Patents on Regenerative Medicine Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus
Vascular Disease Prevention (Discontinued) The Role of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Signaling in Cardiovascular Therapy
Current Signal Transduction Therapy Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Hydrogen Sulfide and its Modulation in Arterial Hypertension and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases
Current Pharmaceutical Design One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Subject Index To Volume 6
Current Molecular Medicine Transbronchial Needle Aspiration (TBNA): Past Present and Future
Current Respiratory Medicine Reviews Editorial (Sulodexide, An Old Drug with Recent Renewed Interest)
Current Vascular Pharmacology Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences The Potential of Statins for Individualized Colorectal Cancer Chemoprevention
Current Drug Targets Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets Diabetic Retinopathy: Current and New Treatment Options
Current Diabetes Reviews